Heron Therapeutics, Inc.
HRTX
Rank in Stocks
#21279
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating... Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
Share Price
$0.3706
Last synced: 2026-11-09
Market Cap
$70.36M
Change (1 day)
26.48%
Change (1 year)
-68.05%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Heron Therapeutics, Inc. (HRTX)
Category
Healthcare
Operating Margin for Heron Therapeutics, Inc. (HRTX)
Operating Margin as of November 2026 TTM: -7.19%
According to Heron Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -7.19%. At the end of 2025 the company had an operating margin of -1.64%.
Operating Margin history for Heron Therapeutics, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -7.19% | 338.41% |
| 2025 | -1.64% | -79.47% |
| 2024 | -7.99% | -90.82% |
| 2023 | -87.07% | -46.32% |
| 2022 | -162.21% | -35.70% |
| 2021 | -252.27% | -2.00% |
| 2020 | -257.41% | 78.34% |
| 2019 | -144.34% | -39.20% |
| 2018 | -237.42% | -62.45% |
| 2017 | -632.36% | -95.27% |
| 2016 | -13,363.17% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | -100.00% |
| 2012 | -3,689.01% | 115.43% |
| 2011 | -1,712.38% | 124.26% |
| 2010 | -763.57% | -5.99% |
| 2009 | -812.21% | -87.22% |
| 2008 | -6,353.66% | 10.76% |
| 2007 | -5,736.17% | 1,539.28% |
| 2006 | -349.92% | 122.64% |
| 2005 | -157.17% | -8.83% |
| 2004 | -172.39% | 26.39% |
| 2003 | -136.39% | 56.95% |
| 2002 | -86.90% | -47.99% |
| 2001 | -167.08% | 30.57% |
| 2000 | -127.96% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -105.37% |
US
|
|
| -149.01% | -79.28% |
US
|
|
| 25.57% | -103.56% |
AU
|
|
| 31.23% | -104.34% |
BE
|
|
| 29.35% | -104.08% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Heron Therapeutics, Inc.'s operating margin
What is Heron Therapeutics, Inc.'s operating margin?
Heron Therapeutics, Inc.'s operating margin is -7.19%, as of Nov 2026.
What was Heron Therapeutics, Inc.'s operating margin in 2025?
In 2025, Heron Therapeutics, Inc.'s operating margin was -1.64%, compared with -7.99% in 2024.
How has Heron Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Heron Therapeutics, Inc.'s operating margin was highest in 2025 (-1.64%) and lowest in 2020 (-257.41%).
How does Heron Therapeutics, Inc.'s operating margin compare with similar companies?
Heron Therapeutics, Inc.'s operating margin (-7.19%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.